By: IPP Bureau
Last updated : April 06, 2026 3:12 pm
Safety was equally impressive. ENV-294 was well tolerated
Enveda, a clinical-stage biotech pioneering small molecules derived from natural chemistry, has announced that its investigational oral therapy, ENV-294, delivered impressive results in a Phase 1b trial for moderate-to-severe atopic dermatitis (AD).
The open-label study enrolled nine adults, including patients who had previously tried systemic therapies without success. Participants received 800 mg of ENV-294 once daily for 28 days, followed by a 14-day observation period.
“ENV-294 is a first-in-class molecule enabled by Enveda’s chemistry-first approach, designed to access entirely new biology,” said Viswa Colluru, Founder and CEO of Enveda.
“Rather than suppressing individual cytokines, it is a non-degrading molecular glue, or ‘LOCKTAC,’ that resets the cellular immune response to chronic inflammation. We are advancing ENV-294 into Phase 2a trials in atopic dermatitis and asthma, with a Phase 2b study planned for mid-2026. Alongside additional clinical programs in IBD and obesity, ENV-294 represents the first-in-class innovation that could alter the treatment landscape and make a meaningful difference to the patient journey.”
The results were striking. Patients saw a 68% reduction in Eczema Area and Severity Index (EASI) scores by Day 28, deepening to 85% by Day 42, two weeks after treatment ended. All participants achieved EASI-50, 78% reached EASI-75, and 56% hit EASI-90.
Notably, 44% achieved a vIGA-AD score of 0 or 1, including two patients with complete skin clearance. One of these had previously failed IL4R-targeted biologic therapy. Responses appeared as early as Day 8 and continued to improve post-treatment, suggesting durable disease modification.
Patients also experienced meaningful reductions in itch and lesion severity, with biomarker data confirming multi-pathway engagement. ENV-294 appears to reconfigure cellular immunity rather than block a single cytokine, a potential paradigm shift in AD therapy.
Safety was equally impressive. ENV-294 was well tolerated, with no serious or severe adverse events, no discontinuations, and no lab, vital sign, or ECG abnormalities. Unlike current systemic treatments, it showed no immunosuppressive safety signals.
“The atopic dermatitis treatment landscape has advanced with biologics and JAK inhibitors, but no oral therapy today delivers JAK-inhibitor-like efficacy without boxed warnings and laboratory monitoring,” said Jonathan Silverberg, Professor of Dermatology at The George Washington University School of Medicine.
“The ENV-294 data, while early, are compelling, with rapid, deep responses by Day 28 that continue to improve after treatment cessation. The biomarker profile also indicates broad activity across Th2, Th17, and Th1 pathways, which is particularly relevant in many atopic dermatitis patients with mixed or non–Th2-driven disease. If confirmed in larger studies, ENV-294 could represent a meaningful advance in the treatment of atopic dermatitis.”
“As a lead investigator, what struck me was how well patients tolerated ENV-294 with no serious or severe adverse events, no discontinuations, and a safety profile distinct from what we typically see with systemic immunosuppressants or JAK inhibitors.
"Equally impressive was the clinical response, with 56% achieving EASI-90 and 44% of patients achieving complete or near-complete skin clearance by Day 42. For patients living with moderate-to-severe atopic dermatitis, the combination of a rapid, deep response in a well-tolerated, once-daily oral therapy is encouraging. These results give me genuine confidence that ENV-294 warrants further investigation in larger trials,” said Leon Kircik, Clinical Professor at Mount Sinai.